中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

242 records (took 0.06 seconds)

    FORMULATION COMPRISING TESTOSTERON UNDECANOATE AND CASTOR OIL
    43.
    发明申请
    FORMULATION COMPRISING TESTOSTERON UNDECANOATE AND CASTOR OIL 审中-公开
    制剂包含试验酯和蓖麻油

    公开(公告)号：WO00059512A1

    公开(公告)日：2000-10-12

    申请号：PCT/EP2000/002677

    申请日：2000-03-27

    IPC: A61K9/48 ,  A61K31/568 ,  A61K47/12 ,  A61K47/44 ,  A61P5/26 ,  A61P15/16 ,  A61P43/00

    CPC classification number: A61K31/568 ,  A61K9/4858

    Abstract: Disclosed is a pharmaceutical formulation in the form of a capsule for oral administration comprising testosterone undecanoate as an active ingredient dissolved in a pharmaceutically acceptable liquid carrier, characterised in that the liquid carrier comprises at least 50 % by weight of castor oil. The choice of castor oil as the liquid carrier, in conjunction with the choice of testosterone undecanoate as the androgen, makes for a solution which can comprise about 200-250 mg/ml of TU. This is a novel achievement for any orally administerable solution of testosterone. The solution may also contain a lipophilic surfactant such as lauroglycol.

    Abstract translation: 公开了用于口服给药的胶囊形式的药物制剂，其包含溶解在药学上可接受的液体载体中的作为活性成分的十一酸睾酮，其特征在于，所述液体载体包含至少50重量％的蓖麻油。 作为液体载体的蓖麻油的选择，结合选择作为雄激素的十一酸睾酮，可以制备可包含约200-250mg / ml TU的溶液。 这是任何可口服给药的睾酮溶液的新成就。 该溶液还可以含有亲脂性表面活性剂，如青霉烯。

    TESTOSTERONE CONTAINING PHARMACEUTICAL COMPOSITION
    45.
    发明申请
    TESTOSTERONE CONTAINING PHARMACEUTICAL COMPOSITION 审中-公开

    公开(公告)号：WO2021156043A1

    公开(公告)日：2021-08-12

    申请号：PCT/EP2021/050930

    申请日：2021-01-18

    Applicant: DIURNAL LIMITED

    Inventor： WHITAKER, Martin ,  PORTER, John ,  ROSS, Richard ,  JONES, Stewart ,  COCKS, Elizabeth

    IPC: A61K31/568 ,  A61K47/44 ,  A61K47/10 ,  A61K47/14 ,  A61P5/26 ,  A61K9/00 ,  A61K9/48

    Abstract: A pharmaceutical composition for adapted for oral administration comprising at least 10 % w/w native testosterone, at least 36% w/w sesame oil, at least 28% w/w propylene glycol monolaurate, at least 9 % w/w ethanol and at least 14 % w/w benzyl alcohol. A dosage regimen for use in a human subject comprising administering at least a first and a second pharmaceutical compositions wherein, the first composition comprises between 2.5-7.5 % w/w native testosterone, sesame oil, propylene glycol monolaurate, ethanol and benzyl alcohol; and the second composition comprises at least 9% w/w native testosterone, sesame oil, propylene glycol monolaurate, ethanol and benzyl alcohol; wherein said first and second compositions are administered orally at least once in a 24- hour period to said human subject to normalise serum testosterone. A process to produce a composition comprising native testosterone comprising i) forming a homogeneous preparation comprising sesame oil, propylene glycol monolaurate, benzyl alcohol and ethanol; ii) adding native testosterone at a concentration of about 13% w/w to said homogeneous preparation to form a combined testosterone preparation; and iii) mixing the combined preparation to dissolve testosterone to form a substantially clear preparation.

    COMBINATION OF AN ACAT1 INHIBITOR AND A CYP1 1 B1 INHIBITOR FOR TREATING DISORDERS ASSOCIATED WITH EXCESS CORTISOL PRODUCTION
    49.
    发明申请
    COMBINATION OF AN ACAT1 INHIBITOR AND A CYP1 1 B1 INHIBITOR FOR TREATING DISORDERS ASSOCIATED WITH EXCESS CORTISOL PRODUCTION 审中-公开
    ACAT1抑制剂和CYP1 1 B1抑制剂联合治疗与过敏性生殖相关的疾病

    公开(公告)号：WO2016164476A3

    公开(公告)日：2016-12-01

    申请号：PCT/US2016026240

    申请日：2016-04-06

    Applicant: MILLENDO THERAPEUTICS INC

    Inventor： MOHIDEEN PHARIS ,  OWENS JULIA CHRISTINE

    IPC: A61K31/17 ,  A61K31/4184 ,  A61K31/444 ,  A61K45/06 ,  A61P5/06 ,  A61P5/26 ,  A61P5/42 ,  A61P5/46

    CPC classification number: A61K31/444 ,  A61K31/17 ,  A61K31/4184 ,  A61K31/4188 ,  A61K45/06 ,  A61K2300/00

    Abstract: A therapeutically effective amount of a combination of: (a) an inhibitor of CYP11B1; and (b) ACAT1 inhibitor N-(2,6-bis(l-methylethyl) phenyl)-N'-((l-(4-(dimethylamino)phenyl)cyclopentyl)-methyl) urea (ATR-101) or a salt thereof; or (a) an inhibitor of CYP11B1; (b) an inhibitor of CYP11B2; and (c) ACAT1 inhibitor N-(2,6-bis(1-methylethyl)phenyl)-N'-((1-(4-(dimethyl-lamino)phenyl)cyclopentyl) -methyl)urea or a salt thereof for use in a method for the treatment of disorders associated with excess Cortisol production, including treatment of Cushing's syndrome.

    Abstract translation: 治疗有效量的组合：（a）CYP11B1抑制剂; 和（b）ACAT1抑制剂N-（2,6-双（1-甲基乙基）苯基）-N' - （（1-（4-（二甲基氨基）苯基）环戊基） - 甲基）脲（ATR-101）或 其盐 或（a）CYP11B1抑制剂; （b）CYP11B2抑制剂; 和（c）ACAT1抑制剂N-（2,6-双（1-甲基乙基）苯基）-N' - （（1-（4-（二甲基 - 氨基）苯基）环戊基） - 甲基）脲或其盐 用于治疗与过量皮质醇生产相关的疾病的方法，包括治疗库兴综合征。

    USE OF FENUGREEK EXTRACT TO ENHANCE PSYCHOLOGICAL, SOMATIC, AND SEXUAL CONDITIONS IN AGING MALES
    50.
    发明申请
    USE OF FENUGREEK EXTRACT TO ENHANCE PSYCHOLOGICAL, SOMATIC, AND SEXUAL CONDITIONS IN AGING MALES 审中-公开
    使用芬尼克提取物增强老年人的心理，生理和性别状况

    公开(公告)号：WO2016134174A1

    公开(公告)日：2016-08-25

    申请号：PCT/US2016/018521

    申请日：2016-02-18

    Applicant: GE NUTRIENTS, INC.

    Inventor： BHASKARAN, Sunil ,  VENKATESH, Ramasamy, Varadarajan ,  VEERAVALLI, Jith

    IPC: A61K36/48 ,  A61P15/10 ,  A61P5/26

    CPC classification number: A61K36/48 ,  A23L33/105

    Abstract: . Novel methods of improving or enhancing psychological, somatic, and sexual conditions in an aging male human subject, by administering fenugreek or fenugreek seeds, or an extract of fenugreek or fenugreek seeds, are described. Novel methods of reducing symptom severity of andropause, improving sexual functions, preventing further decline of sexual hormones, and/or improving sexual hormonal level in an aging male human subject, by administering fenugreek or fenugreek seeds, or an extract of fenugreek or fenugreek seeds, are also described.

    Abstract translation: 。 描述了通过施用葫芦巴或葫芦巴种子或葫芦巴或葫芦巴种子的提取物来改善或增强老年男性人类受试者的心理，体质和性状况的新方法。 通过施用葫芦巴或葫芦巴种子，或葫芦巴或葫芦巴种子的提取物，降低性别功能降低性功能，防止性激素进一步衰退和/或改善老年男性人类受试者的性激素水平的新方法， 也被描述。

Patent Agency Ranking